产品
编 号：F546006
分子式：C18H19N3O
分子量：293.36
分子式：C18H19N3O
分子量：293.36
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 99614-02-5
产品详情
生物活性：
Ondansetron (GR 38032; SN 307) is a highly selective 5-HT3 receptor antagonist, with IC50 value of 103 pM. Ondansetron exerts antiemetic effects by antagonizing 5-HT receptor located on local neurons in the peripheral and central nervous system. Ondansetron suppresses nausea and vomiting caused by chemotherapy and radiation therapy. Ondansetron has orally bioactivity.
体内研究：
Ondansetron (GR 38032；SN 307) (2.4-6 mg/kg；腹腔注射；15 天六次) 在小鼠中 TD50 值为 3.7±0.6 mg/ kg，LD50 为 4.6±0.5 mg/kg。Ondansetron (8 mg/kg；腹腔注射；1 次) 联合 Olanzapine (HY-14541) 在预防 NSCLC 患者的 CINV 方面具有更好的效果，特别是对于后期患者。Ondansetron (2 mg/kg；腹腔注射；连续六天) 通过 5-HT3 受体表现出抗炎作用。Animal Model:NSCLC Patients Treated With Chemotherapy
Dosage:8 mg
Administration:Intraperitoneal Injection (i.p.)
Result:Showed TD50 and LD50 doses with 3.7±0.6 mg/kg and 4.6±0.5 mg/kg, respectively.
Animal Model:Male Swiss Mice with Colitis
Dosage:2 mg/kg
Administration:Intraperitoneal Injection (i.p.)
Result:Showed dramatic reduction in MPO activity and tumor necrosis factor-alpha, interleukin-6 and interleukin-1 beta.
Ondansetron (GR 38032; SN 307) is a highly selective 5-HT3 receptor antagonist, with IC50 value of 103 pM. Ondansetron exerts antiemetic effects by antagonizing 5-HT receptor located on local neurons in the peripheral and central nervous system. Ondansetron suppresses nausea and vomiting caused by chemotherapy and radiation therapy. Ondansetron has orally bioactivity.
体内研究：
Ondansetron (GR 38032；SN 307) (2.4-6 mg/kg；腹腔注射；15 天六次) 在小鼠中 TD50 值为 3.7±0.6 mg/ kg，LD50 为 4.6±0.5 mg/kg。Ondansetron (8 mg/kg；腹腔注射；1 次) 联合 Olanzapine (HY-14541) 在预防 NSCLC 患者的 CINV 方面具有更好的效果，特别是对于后期患者。Ondansetron (2 mg/kg；腹腔注射；连续六天) 通过 5-HT3 受体表现出抗炎作用。Animal Model:NSCLC Patients Treated With Chemotherapy
Dosage:8 mg
Administration:Intraperitoneal Injection (i.p.)
Result:Showed TD50 and LD50 doses with 3.7±0.6 mg/kg and 4.6±0.5 mg/kg, respectively.
Animal Model:Male Swiss Mice with Colitis
Dosage:2 mg/kg
Administration:Intraperitoneal Injection (i.p.)
Result:Showed dramatic reduction in MPO activity and tumor necrosis factor-alpha, interleukin-6 and interleukin-1 beta.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备